Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹64 Cr
Revenue (TTM)
₹289 Cr
Net Profit (TTM)
₹-2 Cr
ROE
10.4 %
ROCE
13.6 %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
20.87
EV/EBITDA
244.7
Div. Yield
0.5 %
Debt to Equity
0.1
Book Value
₹227.3
EPS
₹-5.4
Face value
10
Shares outstanding
3,089,700
CFO
₹9.74 Cr
EBITDA
₹90.16 Cr
Net Profit
₹59.47 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
| -9.2 | -1.4 | -9.4 | -36.7 | -17.8 | 8.2 | 22.6 |
|
BSE Commodities
| -4.9 | -8.2 | -6.3 | 5.0 | 15.1 | 11.3 | 15.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
| -41.9 | 8.7 | -54.2 | 116.1 | 154.3 | 41.2 | 85.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Samrat Pharmachem
|
206.5 | 63.8 | 289.2 | -1.7 | -0.5 | -2.4 | -- | 0.9 |
| 1,319.0 | 6,741.6 | 1,535.0 | 180.7 | 13.7 | 12.7 | 37.3 | 4.5 | |
| 3,311.0 | 14,345.1 | 15,069.6 | 378.2 | 3.0 | 9.9 | 37.9 | 3.7 | |
| 992.8 | 12,600.4 | 11,162.0 | 877.2 | 12.4 | 13.7 | 14.4 | 1.9 | |
| 1,655.3 | 5,861.9 | 5,078.5 | 280.8 | 7.1 | 11.9 | 20.9 | 2.3 | |
| 603.5 | 4,422.4 | 4,308.2 | 34.3 | 0.0 | -0.2 | -- | 0.8 | |
| 2,438.8 | 7,826.3 | 15,622.2 | 1,787.5 | 16.6 | 12.6 | 8.7 | 1.0 | |
| 4,192.6 | 5,717.1 | 1,886.6 | 168.0 | 11.4 | 16.6 | 34 | 4.3 | |
| 5,891.0 | 30,150.3 | 3,077.1 | 545.9 | 25.9 | 18 | 55.2 | 8.0 | |
| 651.9 | 16,625.4 | 14,655.0 | 194.0 | 4.8 | 1.2 | 92.4 | 0.7 |
No Review & Analysis are available.
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc. The company... also exports its products worldwide. Samrat Pharmachem Limited was founded in 1992 and is based in Mumbai, India. Read more
Incorporated
1992
Chairman
Lalit Mehta
Managing Director
Lalit Mehta
Headquarters
Ankleshwar, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Samrat Pharmachem Ltd is ₹206.45 (BSE) as of 02-Apr-2026 IST. Samrat Pharmachem Ltd has given a return of -17.76% in the last 3 years.
Since, TTM earnings of Samrat Pharmachem Ltd is negative, P/E ratio is not available.
The P/B ratio of Samrat Pharmachem Ltd is 0.91 times as on 02-Apr-2026, a 40 discount to its peers’ median range of 1.51 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.59
|
1.35
|
|
2024
|
47.64
|
1.59
|
|
2023
|
6.89
|
1.82
|
|
2022
|
8.72
|
3.20
|
|
2021
|
7.88
|
1.42
|
The 52-week high and low of Samrat Pharmachem Ltd are Rs 425.00 and Rs 190.00 as of 05-Apr-2026.
Samrat Pharmachem Ltd has a market capitalisation of ₹ 64 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Samrat Pharmachem Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹8.55
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.